These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 17174013)

  • 1. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.
    Wakamatsu M; Ishii A; Iwata S; Sakagami J; Ukai Y; Ono M; Kanbe D; Muramatsu S; Kobayashi K; Iwatsubo T; Yoshimoto M
    Neurobiol Aging; 2008 Apr; 29(4):574-85. PubMed ID: 17174013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
    Wakamatsu M; Iwata S; Funakoshi T; Yoshimoto M
    J Neurosci Res; 2008 Feb; 86(3):640-6. PubMed ID: 17896793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
    Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A
    Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.
    Matsuoka Y; Vila M; Lincoln S; McCormack A; Picciano M; LaFrancois J; Yu X; Dickson D; Langston WJ; McGowan E; Farrer M; Hardy J; Duff K; Przedborski S; Di Monte DA
    Neurobiol Dis; 2001 Jun; 8(3):535-9. PubMed ID: 11442360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
    Dong Z; Ferger B; Feldon J; Büeler H
    J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
    Hayashita-Kinoh H; Yamada M; Yokota T; Mizuno Y; Mochizuki H
    Biochem Biophys Res Commun; 2006 Mar; 341(4):1088-95. PubMed ID: 16460685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
    Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
    Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein.
    Wakamatsu M; Ishii A; Ukai Y; Sakagami J; Iwata S; Ono M; Matsumoto K; Nakamura A; Tada N; Kobayashi K; Iwatsubo T; Yoshimoto M
    J Neurosci Res; 2007 Jun; 85(8):1819-25. PubMed ID: 17465029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates.
    Purisai MG; McCormack AL; Langston WJ; Johnston LC; Di Monte DA
    Neurobiol Dis; 2005 Dec; 20(3):898-906. PubMed ID: 16006134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.
    Robertson DC; Schmidt O; Ninkina N; Jones PA; Sharkey J; Buchman VL
    J Neurochem; 2004 Jun; 89(5):1126-36. PubMed ID: 15147505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
    Chu Y; Kordower JH
    Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prosurvival effect of human wild-type alpha-synuclein on MPTP-induced toxicity to central but not peripheral catecholaminergic neurons isolated from transgenic mice.
    Pérez-Sánchez F; Milán M; Buendía P; Cano-Jaimez M; Ambrosio S; Rosenthal A; Fariñas I
    Neuroscience; 2010 May; 167(2):261-76. PubMed ID: 20156526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein.
    Yavich L; Oksman M; Tanila H; Kerokoski P; Hiltunen M; van Groen T; Puoliväli J; Männistö PT; García-Horsman A; MacDonald E; Beyreuther K; Hartmann T; Jäkälä P
    Neurobiol Dis; 2005 Nov; 20(2):303-13. PubMed ID: 16242637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.
    Ulusoy A; Febbraro F; Jensen PH; Kirik D; Romero-Ramos M
    Eur J Neurosci; 2010 Aug; 32(3):409-22. PubMed ID: 20704592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
    Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
    Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D2 receptor knockout mice develop features of Parkinson disease.
    Tinsley RB; Bye CR; Parish CL; Tziotis-Vais A; George S; Culvenor JG; Li QX; Masters CL; Finkelstein DI; Horne MK
    Ann Neurol; 2009 Oct; 66(4):472-84. PubMed ID: 19847912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons.
    Ulusoy A; Björklund T; Buck K; Kirik D
    Neurobiol Dis; 2012 Sep; 47(3):367-77. PubMed ID: 22659302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.